NCT06800261View on ClinicalTrials.gov

Clinical Trial of PCV24 in Infants Aged 2-23 Months

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

September 30, 2025

Study Completion Date

June 30, 2026

Conditions
Pneumococcal Infectious Disease
Interventions
BIOLOGICAL

Sinovac PCV24

Sinovac PCV24 (0.5 mL) is administered intramuscularly according to different immunization schedules.

BIOLOGICAL

Prevnar®

Prevnar® (0.5 mL) is administered intramuscularly according to different immunization schedules.

Trial Locations (1)

250014

Shandong Provincial Center for Disease Control and Prevention, Jinan

All Listed Sponsors
lead

Sinovac Life Sciences Co., Ltd.

INDUSTRY